When to Start HIV/AIDS Treatment: Research
 Journal Club: In Early HIV Infection, Little Reason to Delay Therapy (January 8, 2012)
From Journal Watch
- Study Finds That Long-Term Use of HIV Drugs Doesn't Increase Non-AIDS Death Risk (December 8, 2011)
From The Body
- Earlier Versus Later Start of Antiretroviral Therapy in HIV-Infected Adults With Tuberculosis (October 31, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Treating TB, HIV Co-Infections Early, Aggressively Can Save Lives, Multiple Studies Show (October 20, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
 Life Expectancy Keeps Rising for People With HIV, Particularly When They Start Treatment Early, Study Finds (October 14, 2011)
From The Body
- CASCADE: When to Start, (Yet) Another Take (October 3, 2011)
From Journal Watch
- Study Sheds Light on When to Start Antiretroviral Therapy (September 27, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- No Difference in AIDS-Free Survival in Children Starting ART With a CD4% Between 15%-24% Compared to Deferring Until Less Than 15% in the PREDICT Trial (July/August 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Randomized Trial Supports Earlier Treatment (July 20, 2011)
From HIVandHepatitis.com
- Early Treatment Reduces Serious Illnesses by 40 Percent in HPTN 052 (July 19, 2011)
From AIDSmeds.com
- Studies Confirm PrEP, Early ART Prevent HIV Transmission (July 18, 2011)
From HIVandHepatitis.com
- HIV Treatment as Prevention: 96 Percent Reduction of Sexual Transmission in HPTN 052 Study (July 18, 2011)
From AIDSmeds.com
- HPTN 052: Early Treatment Reduces Serious Illness by 40 Percent (July 18, 2011)
From aidsmap.com
- Treatment Is Prevention: HPTN 052 Study Shows 96 Percent Reduction in Transmission When HIV-Positive Partner Starts Treatment Early (July 18, 2011)
From aidsmap.com
- CD4s Above 500: HIV Treatment Need Still Unclear (July 6, 2011)
In POZ
- Antiretroviral Drugs Can Significantly Lower Risk of Contracting HIV, but is the Public Buying It? (June 2, 2011)
In HealthCanal.com
- Study Suggests That Positive Baby Boomers Should Start Treatment Earlier (May 31, 2011)
- Continue HIV Treatment While Data Is Collected on Treatment as Prevention (May 27, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Global Health Community Must Recognize Merits of HIV Treatment as Prevention (May 20, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Initiating Anti-HIV Therapy at High CD4 Count Increases AIDS-Free Survival (April 28, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Study Finds that San Fran's Aggressive New Policy Could Have Huge Impact on MSM (April 16, 2011)
In San Francisco Chronicle
- Paul Sax, M.D., on New HIV Treatment Research: Even When You Think You Should Wait, It's Probably Time to Start (April 8, 2011)
From Journal Watch
- NIH Study Examines Best Time for Healthy HIV-Infected People to Begin Antiretrovirals (March 7, 2011)
From U.S. National Institute of Allergy and Infectious Diseases
- At Long Last, a Published When-to-Start Trial (December 8, 2010)
Part of "Top HIV/AIDS-Related Clinical Developments of 2010," by David Wohl, M.D.
From The Body
- Delaying Treatment for HIV Can Become Costly (November 29, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Study Finds Early HIV Treatment May Improve Long-Term Response to Other Infections (September 28, 2010)
From National Institute of Allergy and Infectious Diseases
- Late Access to HIV Care (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- To Start, or Not to Start? (July/August 2010)
Leading advocates and physicians offer their thoughts on a new study.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- CASCADE Analysis Finds Antiretroviral Treatment Benefits Are Evident Below CD4 Count of 500, Uncertain Above This Level (July 23, 2010)
From aidsmap.com
- Under the Radar: July 22 (July 22, 2010)
In The XVIII International AIDS Conference, from The Body
- Starting HAART: When to Take the First Step? (July 20, 2010)
To read PDF, click here.
From Henry J. Kaiser Family Foundation
- Inflammatory Debate Over When to Start (Summer 2010)
To read PDF, click here.
In TAGline, from Treatment Action Group
- Early HIV Treatment Reduces Death, Likelihood of TB, Study Finds (July 15, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Can "Test and Treat" Actually Work? (March 8, 2010)
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Is HIV Treatment HIV Prevention? (Summer/Fall 2009)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Study Suggests Immune Systems of Untreated HIV-Infected Individuals May Deteriorate Faster Than Previously Thought (July 29, 2009)
From U.S. National Institute of Allergy and Infectious Diseases
- Treating HIV Earlier Could Save 76,000 Lives in South Africa (July 23, 2009)
A new study finds that initiating antiretroviral therapy when a patient's CD4+ cell count drops below 350 cells/mm3 could save 76,000 lives in South Africa alone over the next five years.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Delays in Starting Treatment Common in ART Programs (July 23, 2009)
Late initiation of antiretroviral treatment following diagnosis is contributing to the continuing high death rate among people who present with low CD4+ cell counts in eight sub-Saharan African countries.
From aidsmap.com
- HIV's Silent Dangers Make Early HIV Treatment Critical, Expert Says (July 21, 2009)
A discussion about inflammation, early treatment and universal treatment access -- Wafaa El-Sadr, M.D., M.P.H., United States.
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- IAS Welcomes Trial Findings Showing Benefits of Earlier Antiretroviral Treatment (June 19, 2009)
From International AIDS Society
- Starting Treatment at Lower CD4 Cell Counts Increases Risk of HIV Drug Resistance (June 12, 2009)
From aidsmap.com
- Questions and Answers: The CIPRA HT 001 Clinical Trial (June 8, 2009)
From U.S. National Institute of Allergy and Infectious Diseases
- Starting Antiretroviral Therapy Earlier Yields Better Clinical Outcomes (June 8, 2009)
Interim review leads to early end of clinical trial in Haiti.
From U.S. National Institute of Allergy and Infectious Diseases
- Study Shows Decreased Risk of Death From Opportunistic Infections With Earlier Antiretroviral Treatment (May 19, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Effect of Early Versus Deferred Antiretroviral Therapy for HIV on Survival (April 30, 2009)
In The New England Journal of Medicine
- Early Initiation of Antiretroviral Therapy Improves HIV Survival Rates, Study Says (April 30, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Timing of Initiation of Antiretroviral Therapy in AIDS-Free HIV-1-Infected Patients: a Collaborative Analysis of 18 HIV Cohort Studies (April 18, 2009)
In The Lancet
- Should the CD4 Threshold for Starting ART Be Raised? (April 18, 2009)
In The Lancet
- Study Supporting Earlier Antiretroviral Treatment "Not Definitive," NEJM Editorial Says (April 10, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- When to Start Treatment: Leave it No Later Than 350, Major Studies Agree (April 9, 2009)
From aidsmap.com
- Effect of Early Versus Deferred Antiretroviral Therapy for HIV on Survival (April 9, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Delaying HAART Might Prevent Complete Immune System Recuperation, Study Says (April 9, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Study Supports Earlier Antiretroviral Treatment, Researchers Call for Amended Recommendations (April 9, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Earlier Antiretroviral Treatment Could Reduce Risk of Death in HIV-Positive People, Study Finds (April 2, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- More Evidence Favors Early Treatment (Winter/Spring 2009)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Treating AIDS Infection Immediately Might Stall Immune Decay (February 17, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Starting HAART Earlier Might Reduce Mortality Rates, Study Says (February 12, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Ever Upward: "When to Start" Debate Turns to CD4+ Cell Count of 500 (February 9, 2009)
Dueling studies -- one presented by Mari Kitahata, M.D., the other by Jonathan Sterne, M.D. -- offer strikingly different views on the benefits of HAART initiation at a CD4+ threshold of 500. However, both appear to solidify the wisdom of starting therapy before CD4+ cell count drops below 350.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Starting Therapy Earlier Found to Improve Survival (January/February 2009)
Study raises the implications of more testing, less transmission.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Starting Treatment at CD4 Above 350 May Bring Extra Immune Benefits, Study Says (January 13, 2009)
From aidsmap.com
- Earlier Treatment of HIV Could Help HIV-Positive People Avoid Long-Term Complications, Recommendations Say (August 5, 2008)
A panel of the International AIDS Society-USA has issued new recommendations for when physicians should initiate HAART.
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- HIV Meds May Help Prevent Illness and Death at CD4 Counts Above 350, Study Finds (April 14, 2008)
- Starting HIV Meds Early Is Better for Your Health Than Waiting, Study Says (April 14, 2008)
- CROI: Could earlier ART Reduce Risk of Death from Non-AIDS Related Illnesses in People With HIV? (February 6, 2008)
From aidsmap.com
- New HIV Treatment Guidelines in Europe Recommend Starting Meds at 350 (October 25, 2007)
- Possible Benefit to Starting Treatment at High CD4 Count, Massive Study Finds (August 24, 2007)
The study of more than 17,000 people who had never taken HIV meds found that, even among those with a CD4 count well over 350, the higher the count, the less likely they were to develop an AIDS-related illness or die.
From aidsmap.com
- Current Options for First-Line Treatment of HIV Infection (July 2, 2007)
From The Body PRO
- First-Line Therapy: What Should You Take? (July 2, 2007)
Discusses Choosing Among Drug Classes , Efavirenz-Based Combinations , Ritonavir-Boosted PI-Based Regimens and Considering NRTIs.
From The Body PRO
- Three Months of Meds in Early Infection May Slow Down HIV in the Long Run (June 26, 2007)
From aidsmap.com
- Voices Grow Louder in Support of Earlier HAART Initiation (January 12, 2007)
From aidsmap.com
- Large Study Backs Starting HIV Treatment When CD4 Count Is Above 350 (January 9, 2007)
From aidsmap.com
- Veterans Medical Affairs Researchers to Request NIH Funding for Study Examining Best Time to Start Antiretroviral Treatment (January 8, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- CD4 Percentage May Be Useful for Deciding Whether to Start HIV Treatment (January 5, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Strategic Use of Antiretroviral Therapy: What to Use and When? (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Two Studies Examine Potential Benefit of Beginning ART During Acute Infection (September 1, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Optimal Timing of HAART Initiation Does Not Differ With Regimens That Include Efavirenz or Ritonavir-Boosted Protease Inhibitors (August 15, 2006)
In XVI International AIDS Conference
- To Start or Not to Start? CD4 Percentage May Provide Guidance (August 29, 2005)
[Archived Article]
Among people with a CD4 count above 350, HIV disease progression is found to be 3.6 times more likely for those with a CD4 percentage below 17%.
From aidsmap.com
- Tangle of Interests and Disclosure Omissions Cracks Authors' Case for Early, Aggressive Treatment (January 2005)
[Archived Article]
AIDS advocate Mike Barr expresses concern over the influence of drug company money on HIV clinical practice -- and over some journals' lax disclosure policies.
In TAGline, from Treatment Action Group
- HIV JournalView: When to Start Antiretroviral Therapy? (December 2004)
[Archived Article]
Several articles in Clinical Infectious Diseases debate starting treatment earlier in infants and adults than current guidelines recommend.
From The Body PRO
- Articles Debate Starting HIV Therapy at CD4 Count Over 350 (November 23, 2004)
[Archived Article]
From aidsmap.com
- Injection Drug Users Should Start HAART Earlier, Study Suggests (September 8, 2004)
[Archived Article]
From aidsmap.com
- Study Supports Early Start to NNRTI-Based HAART (July 1, 2004)
[Archived Article]
A small London study finds that early treatment causes viral load to drop to levels similar to long-term HIV nonprogressors.
In Journal of AIDS
- Update on the Treatment of Acute and Early HIV Infection (May 2004)
[Archived Article]
Details of a talk by Dr. Martin Markowitz of the Aaron Diamond AIDS Research Center and Dr. Bruce Walker of Harvard Medical School; includes a discussion of drug resistance transmission.
In The PRN Notebook
- Adherence, not Baseline CD4 Cell Count, Linked to CD4 Cell Gain on HAART (February 25, 2004)
[Archived Article]
New support for those who feel treatment should be delayed until a patient's CD4 cell count falls near 200.
From aidsmap.com
- Little Benefit Seen for Treatment During Acute Infection (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Gastrointestinal Side Effects Lead One in Eight to Change HAART Regimen in First Year of Treatment (November 27, 2003)
[Archived Article]
More than half of new HAART patients were also found to switch or stop their initial regimens within the first year, often without consulting their doctors.
From aidsmap.com
- Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 x 109 Cells/L (November 18, 2003)
[Archived Article]
In Annals of Internal Medicine
- NNRTI-Based HAART Associated With Quicker CD4 Cell Gains Than PI-Based Therapy (November 13, 2003)
[Archived Article]
Most of the patients in this large but non-randomized Canadian study were taking nevirapine (Viramune).
In The XIII International AIDS Conference, from aidsmap.com
- Induction/Maintenance Approach Revived -- But Will Patients Stick With It? (October 28, 2003)
[Archived Article]
From aidsmap.com
- Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
[Archived Article]
To read PDF, click here.
From U.S. Food and Drug Administration
- Early Response to HAART Means Longer Survival (October 2003)
[Archived Article]
In HIV Treatment ALERTS!, from The Center for AIDS
- Interim Analysis of Failure of Tenofovir/Abacavir/3TC Regimen (September 16, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- No Major Renal Problems With Tenofovir Were Identified in the Naive Population Evaluated in the GS 903 Study (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Kaletra "Monotherapy" Safe and Efficacious for Treatment-Naive Patients (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Treatment Regimens Containing Efavirenz, Nevirapine or Kaletra Are the Most Potent Options for Patients Starting Therapy (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Trizivir Plus Efavirenz Potent for Naive Patients With Low CD4 Counts and High Viral Loads (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Efavirenz or Nevirapine Regimens Are More Potent Than Trizivir for Initial Therapy (September 15, 2003)
[Archived Article]
A 100-patient Spanish study confirms the findings of ACTG 5095.
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Recent Advances in the Clinical Management of the Antiretroviral-Naive Patient (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Emergence of Resistance-Associated Mutations Over 96 Weeks in Patients Initiating ABC/3TC + d4T, EFV or APV/r (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Abacavir Not Inferior to AZT in Treatment-Naive Patients (September 14, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- When to Begin Highly Active Antiretroviral Therapy? Evidence Supporting Initiation of Therapy at CD4+ Lymphocyte Counts <350 Cells (September 12, 2003)
[Archived Article]
In Clinical Infectious Diseases
- A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens Versus a 3-Drug Regimen, in Advanced Human Immunodeficiency Virus Disease (September 1, 2003)
[Archived Article]
Patients with advanced HIV are found to benefit the most from HAART regimens containing efavirenz (Sustiva), as opposed to regimens containing nelfinavir (Viracept) or no NNRTI at all.
In Journal of Infectious Diseases
- Viread, Epivir and Ziagen Combination -- Failure in Naive Patients With a Once-Daily Regimen (September/October 2003)
[Archived Article]
Daniel S. Berger, M.D., chief investigator in study ESS30009, examines what went wrong.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Wait Six Months After HIV Treatment Begins to Determine Prognosis, Study Says (August 29, 2003)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
[Archived Article]
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration
- Abacavir/3TC/Tenofovir Combination Failure in Treatment-Naive Patients (July 14, 2003)
[Archived Article]
Analysis by Timothy Wilkin, M.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Trizivir Often Successful in Treatment-Naive Patients; Resistance Testing Key for Failures (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- CD4 Count at Treatment Initiation Has Decreased Over the Years (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Nevirapine- Versus Efavirenz-Containing Three-Drug Regimens (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Another Look at Induction Maintenance Therapy (July 14, 2003)
[Archived Article]
48-week data on Trizivir and efavirenz in treatment-naive patients.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- FTC Potent Within a HAART Regimen in Treatment-Naive HIV-Infected Patients With High Viral Loads (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Forty-Eight Week Data From FTC-d4T Comparison in Treatment-Naive Patients (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Addition of Abacavir Does Not Appreciably Enhance the Antiviral Potency of a Standard Triple-Therapy Regimen (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- For Potency Tenofovir Equals d4T but Tenofovir Beats d4T With Less Frequent and Common Side Effects (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Abacavir/3TC/Tenofovir Combination Fails in Treatment-Naive Patients (July 14, 2003)
[Archived Article]
Analysis by Benjamin Young, M.D., Ph.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Comparison of Once-Daily FTC Vs. Twice-Daily Abacavir in a Regimen for Drug-Naive Patients (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- More Results Reported on Study 903: Tenofovir + 3TC + Efavirenz Vs. d4T + 3TC + Efavirenz (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Efavirenz-Based HAART Outperforms a Triple Nucleoside Regimen in Clinical Practice (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- ACTG 5095: Efavirenz-Based Regimens Outperform Triple Nucleoside Combination (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Early HAART Extends Life, Costs Less, Study Says -- Despite Cardiovascular Risks (June 11, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- The Buzz: Anatomy of a Study -- Trizivir vs. Sustiva (May/June 2003)
[Archived Article]
A closer look at ACTG 5095, which examined the use of Trizivir and efavirenz in several first-line treatment regimens.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- CROI 2003: When, and With What, to Initiate Antiretroviral Treatment (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Is HAART for Primary/Early HIV Infection Associated With Improved Outcomes After Treatment Discontinuation? (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Earlier Initiation of HAART Better Preserves Functional Immune Competence Even in Persons Who Achieve "Normal" CD4+ T-Cell Counts (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- When to Start ARV Therapy: Where Are We Now? (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- When to Start Antiretroviral Therapy? (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Prognosis of HIV-1 Infected Drug-Naive Patients Starting Potent Antiretroviral Therapy: Multi-Cohort Analysis of 12,040 Patients (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Initiating Antiretroviral Therapy During HIV Infection (November 28, 2001)
[Archived Article]
An editorial.
In Journal of the American Medical Association
- HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load (November 28, 2001)
[Archived Article]
In Journal of the American Medical Association
- New Finding May Help Doctors Prevent HIV Drug Resistance (November 22, 2001)
[Archived Article]
From U.S. National Institute of Allergy and Infectious Diseases
- Initiation of Highly Active Antiretroviral Therapy (HAART) at CD4 Level 350: Assessment of Disease Progression, and Drug Failure, Toxicity, and Resistance (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- When to Start Antiretroviral Therapy; Considerations in Choosing an Initial Regimen; When to Change Regimens; Options for Managing Failure (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Optimizing Available Antiretroviral Therapies (February 8, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Low Lymph Node Viral Load Despite High Viremia in Seroconverters Supports Early HAART Intervention (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- CD4 + Lymphocyte Level Is Better than HIV-1 Plasma Viral Load in Determining When to Initiate HAART (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Long-Term Survival After Initiation of Antiretroviral Therapy (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Cohort Studies Suggesting Immediate HAART Confers No Extra Benefit Compared with Deferred HAART in HIV-Infected Persons CD4 >200 cells/mm3 (March 2000)
[Archived Article]
In TAGline, from Treatment Action Group
- A Call for More Cautious Antiretroviral Treatment (February 18, 2000)
[Archived Article]
From AIDS Treatment News
- CD4 Nadir and Disease Progression (April 1999)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
|
Advertisement
|
Email
Glossary
